Connor, Clark & Lunn Investment Management Ltd. Actinium Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 13, 2021	SELL	$7.62 - $9.79 $88,110 - $113,201	-11,563 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$7.8 - $12.64 $90,191 - $146,156	11,563 New	11,563 $90,000

Others Institutions Holding ATNM

# of Institutions

Shares Held

6.88M

Call Options Held

39.2K

Put Options Held

Black Rock Inc. New York, NY

1.88M
Shares

$2.38 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

1.38M
Shares

$1.76 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

663K
Shares

$842,351
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

492K
Shares

$624,767
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

330K
Shares

$418,705
0.0% of portfolio

View Full List

About Actinium Pharmaceuticals, Inc.

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $32M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

More about ATNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account